NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Company Data

Name NeuroSense Therapeutics Ltd. - Ordinary Shares

Company NeuroSense Therapeutics Ltd.

Symbol NRSN

Website https://www.neurosense-tx.com

Primary Exchange

NASDAQ

ISIN IL0011809592

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Alon Ben-Noon

Market Capitalization 28 Mio

Country Israel

Currency USD

Employees 0,0 T

Address Building B, 4672562 Herzliya

IPO Date 2021-12-09

Ticker Symbols

Name	Symbol
Frankfurt	H1Z.F
NASDAQ	NRSN

More Shares

Investors who hold NeuroSense Therapeutics Ltd. - Ordinary Shares also have the following shares in their portfolio:

DOCKS PETR.AMBES EO 7,65 Share

DXC CAP. FDG 21/27 REGS Bond

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog